Tempest Therapeutics
TPST
24 hedge funds and large institutions have $4.7M invested in Tempest Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 9 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.1% more ownership
Funds ownership: 0.65% → 0.74% (+0.1%)
12% less call options, than puts
Call options by funds: $185K | Put options by funds: $210K
14% less funds holding
Funds holding: 28 → 24 (-4)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
35% less capital invested
Capital invested by funds: $7.29M → $4.7M (-$2.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$336K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$307K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$166K |
| 4 |
BlackRock
New York
|
+$140K |
| 5 |
VF
Virtu Financial
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$125K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$90.6K |
| 3 |
Jane Street
New York
|
-$82.3K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$78.8K |
| 5 |
HF
HRT Financial
New York
|
-$50K |
TPST Hedge Fund Activity: Q2 2024 in Review
24 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2024, worth a combined $4.7M — down 35% from $7.29M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TPST and 6 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $336K. The largest seller was Simplex Trading, cutting an estimated $125K.
- 24 institutional investors held Tempest Therapeutics (TPST) as of Q2 2024, down from 28 in Q1 2024.
- Funds reported $4.7M of Tempest Therapeutics stock for Q2 2024, down 35% quarter-over-quarter.
- 6 funds opened new Tempest Therapeutics positions in Q2 2024 and 9 closed out, a net change of -3 holders.
- The largest Tempest Therapeutics buyer in Q2 2024 was GSA Capital Partners, an estimated $336K added.
- The largest Tempest Therapeutics seller in Q2 2024 was Simplex Trading, an estimated $125K sold.
Based on aggregated 13F filings for Q2 2024.